BFRIW

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-465 ExitQ3 2024 $465 -- $0.0342

Insider Trades

Name	Value	Action	Price	Last Price
Biofrontera AGDirector, 10 Percent Owner: $23k shares BuySep 16, 2025 $0.0006 $0.0342

News

globenewswire.comBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026globenewswire.comMay 21

Trade BFRIW

About Biofrontera Inc.

Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.

CEO: Hermann Luebbert
IPO Date: Oct 29, 2021

Market Data

Open: $0.0225
High: $0.0225
Low: $0.0225
Volume: 10
Avg Volume: 4.1K
52W High: $0.0971
52W Low: $0.0225

Valuation

Market Cap: $9.5M
Enterprise Value: $14M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$13.4M
Revenue: $41.7M
Net Income: -$10.5M
Cash: $6.4M
Debt: $6.2M

Events

EarningsAug 7

EPS est. -0.105